<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01304563</url>
  </required_header>
  <id_info>
    <org_study_id>HKU-2010-149</org_study_id>
    <nct_id>NCT01304563</nct_id>
  </id_info>
  <brief_title>2010/2011 Trivalent Influenza Vaccination</brief_title>
  <official_title>Safety and Efficacy of Dose Sparing Intradermal 2010/2011 Trivalent Influenza Vaccination With the Novel Microneedle Delivery Device</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hospital Authority, Hong Kong</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The University of Hong Kong</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Intradermal influenza vaccination may result in better efficacy when compare to intramuscular
      vaccination.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, randomized, single centre trial in the Queen Mary Hospital. We aim to
      recruit 400 subjects [with a minimum of 50 subjects per group] who would be qualified for the
      Hospital Authority (HA)/ Centre for Health Protection (CHP) Mass Vaccination Program for
      2010/2011 TIV. These patients include all elderly at the age of 65 or above and all adult
      patients at the age of 21 or above with chronic illness (or healthcare workers). Subjects
      will be randomly assigned into 4 groups: Group 1 (ID1) to receive a single low-dose
      intradermal injection of 2010/2011 TIV, with a microneedle device. Group 2 (ID2) to receive a
      single higher low-dose intradermal injection of 2010/2011 TIV with a microneedle device.
      Group 3 (IM15) to receive a single full-dose (15ug) standard 2010/2011 TIV delivered
      intramuscularly by conventional needle. Group 4 (INT) to receive a single low-dose
      intradermal injection of 2010/2011 TIV, with Intanza® needle. The 2010/2011 TIV used will be
      Fluzone®, Sanofi-Pasteur for group 3 and Intanza®, Sanofi-Pasteur for group 1,2 and 4.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">February 2011</completion_date>
  <primary_completion_date type="Actual">February 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>seroconversion rate</measure>
    <time_frame>day 21</time_frame>
    <description>Seroconversion rate (percentage of subjects with a fourfold increase in antibody titres, providing a minimal post vacination titre of 1:40) on day 21 by TIV 2010/2011 hemagglutination inhibition (HI) between the ID and IM groups</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>30 minutes post vaccination</time_frame>
    <description>Adverse events secondary to vaccination with different devices</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seroprotection rate</measure>
    <time_frame>Day 21</time_frame>
    <description>percentage of subjects with a post vaccination titre of at least 1:40</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">240</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>IM15</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>15 mcg TIV 2010/2011 influenza vaccine delivered via intramuscular injection (control)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ID1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Low dose TIV 2010/2011 influenza vaccine delivered via intradermal injection (MicronJet)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ID2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Higher low dose TIV 2010/2011 influenza vaccine delivered via intradermal injection (MicronJet)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>INT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Low dose TIV 2010/2011 influenza vaccine delivered via a short needle intradermal device</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>TIV 2010/2011 influenza vaccine</intervention_name>
    <description>TIV 2010/2011 influenza vaccine Intramuscular: 15 mcg TIV 2010/2011 vaccine x 1: Control</description>
    <arm_group_label>IM15</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>TIV 2010/2011 influenza vaccine</intervention_name>
    <description>Low dose TIV 2010/2011 influenza vaccine delivered via intradermal injection x 1: Experimental</description>
    <arm_group_label>ID1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>TIV 2010/2011 influenza vaccine</intervention_name>
    <description>Higher lower dose TIV 2010/2011 influenza vaccine delivered via intradermal injection x 1: Experimental</description>
    <arm_group_label>ID2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>INT</intervention_name>
    <description>Low dose TIV 2010/2011 influenza vaccine delivered via a short needle intradermal device x 1: Experimental</description>
    <arm_group_label>INT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All participants qualified for the HA/ CHP Mass Vaccination Program for TIV 2010/2011
             seasonal influenza as stated above: including all elderly at the age of 65 or above
             and all adult patients at the age of 21 or above that are either healthcare workers or
             that have a chronic illness including hypertension, diabetes mellitus, ischemic heart
             disease, cerebrovascular disease, thyroid disease and chronic renal failure.

          -  All patients give written informed consent.

          -  Subjects must be available to complete the study and comply with study procedures.

        Exclusion Criteria:

          -  Clinically significant immune-related diseases, significant recent co-morbidities and
             pregnant volunteers.

          -  History or any illness that might interfere with the results of the study or pose
             additional risk to the subjects due to participation in the study

          -  Have a known allergy to eggs or other components of the Study Vaccines (including
             gelatin, formaldehyde, octoxinol, thimerosal, and chicken protein), or history of any
             anaphylaxis, serious vaccine reactions, to any excipients.

          -  Have immunosuppression as a result of an underlying illness or treatment, or use of
             anticancer chemotherapy or radiation therapy (cytotoxic) within the preceding 36
             months.

          -  Have an active neoplastic disease or a history of any hematologic malignancy.

          -  Have known active human immunodeficiency virus (HIV), Hepatitis B, or Hepatitis C
             infection or autoimmune hepatitis and cirrhosis.

          -  History of progressive or severe neurological disorders or Guillain-Barré Syndrome.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The University of Hong Kong, Queen Mary Hospital</name>
      <address>
        <city>Hong Kong</city>
        <state>Hong Kong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 23, 2011</study_first_submitted>
  <study_first_submitted_qc>February 23, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 25, 2011</study_first_posted>
  <last_update_submitted>February 23, 2011</last_update_submitted>
  <last_update_submitted_qc>February 23, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 25, 2011</last_update_posted>
  <responsible_party>
    <name_title>Dr Ivan FN Hung</name_title>
    <organization>The University of Hong Kong</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

